Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 14/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 10/20 | 0.40 |
| ▸ | CCR6 | P51684 | 3/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.37 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21624773 | 1.00 | CYP11B2 (0.40) | CYP11B2CYP11B1CCR6CYP19A1CYP2C9 | |
| SCHEMBL23387230 | 0.87 | NOTUM (0.44) | SMPD3 | |
| SCHEMBL23387339 | 0.87 | NOTUM (0.44) | SMPD3 | |
| SCHEMBL23387232 | 0.87 | NOTUM (0.44) | SMPD3 | |
| SCHEMBL29689525 | 0.86 | CTSK (0.46) | — | |
| SCHEMBL15286551 | 0.84 | CHRNB2 (0.52) | HRH4SMPD3 | |
| SCHEMBL21624638 | 0.81 | CYP11B2 (0.42) | CYP11B2 | |
| SCHEMBL21624636 | 0.81 | CYP11B2 (0.42) | CYP11B2 | |
| SCHEMBL23387377 | 0.80 | CHRNB2 (0.51) | HRH4SMPD3 | |
| SCHEMBL23387374 | 0.80 | CHRNB2 (0.51) | HRH4SMPD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020017569-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日本ケミファ株式会社 | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | TRPV3, CACNA1G, TRPV2 | CYP11B2 2135/4885CYP11B1 2920/4885CCR6 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.